Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a.
Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse.
Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations.